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Background: Evidence of psychological treatment efficacy is strongly needed in ALS,
particularly regarding long-term effects.
Methods: Fifteen patients participated in a hypnosis treatment and self-hypnosis training
protocol after an in-depth psychological and neurological evaluation. Patients’ primary
caregivers and 15 one-by-one matched control patients were considered in the study.
Measurements of anxiety, depression and quality of life (QoL) were collected at the
baseline, post-treatment, and after 3 and 6 months from the intervention. Bayesian
linear mixed-models were used to evaluate the impact of treatment and defense style
on patients’ anxiety, depression, QoL, and functional impairment (ALSFRS-r), as well as
on caregivers’ anxiety and depression.
Results: The statistical analyses revealed an improvement in psychological variables’
scores immediately after the treatment. Amelioration in patients’ and caregivers’ anxiety
as well as caregivers’ depression, were found to persist at 3 and 6 months follow-ups.
The observed massive use of primitive defense mechanisms was found to have a
reliable and constant buffer effect on psychopathological symptoms in both patients
and caregivers. Notably, treated patients decline in ALSFRS-r score was observed to
be slower than that of control group’s patients.
Discussion: Our brief psychodynamic hypnosis-based treatment showed efficacy both
at psychological and physical levels in patients with ALS, and was indirectly associated
to long-lasting benefits in caregivers. The implications of peculiar psychodynamic factors
and mind-body techniques are discussed. Future directions should be oriented toward a
convergence of our results and further psychological interventions, in order to delineate
clinical best practices for ALS.
Keywords: amyotrophic lateral sclerosis (ALS), hypnosis, anxiety, depression, quality of life, defense
mechanisms, ALSFRS-r, psychodynamic intervention
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Introduction
Amyotrophic Lateral Sclerosis (ALS) erodes patients’ personal
autonomy and their own freedom in many dimensions
of existence. This relentless syndrome mainly affecting the
voluntary motor system is characterized by increasing weakness,
spasticity, and dysarthric speech. Potential executive dysfunction
has been described, susceptibly to demographic variables
(Palmieri et al., 2014), in a relevant proportion of cases
(Abrahams, 2013). The disease is also featured by secondary
symptoms such as pain (Pagnini et al., 2012a), sleep disorders
(Blackhall, 2012), emotional lability (Palmieri et al., 2009) and
fasciculations (Rana et al., 2009), that generate from mild
to severe discomfort in everyday living. In the late stages
of the disease, progressing muscular degeneration can evolve
in a “locked-in” state in which conscious patients becomes
progressively paralyzed and voiceless (Borasio et al., 2001). Death
usually occurs due to respiratory failure within 3–4 years from the
onset, unless life is protracted by tracheostomy and long term-
mechanical ventilation (LTMV). In this case, the patient’s life can
be extended 10 years or more after the onset in locked-in state
(Vianello et al., 2011).
Among the wide range of reactions in which a human
being could react to the diagnosis of ALS and its devastating
consequences, such as apathy, denial (Ferro et al., 1987) stoicism
(Rabkin et al., 2000), resentment, hate, hope (Oster and Pagnini,
2012), or suicidal ideation (Palmieri et al., 2010a), anxiety and
depression are probably the most expected features. While their
real prevalence is still uncertain (Pagnini, 2013) most studies
report values around 30% for anxiety and 40% for depression
with some studies reporting values up to 70% for both (Kurt et al.,
2007; Wicks et al., 2007; Palmieri et al., 2009; Pagnini, 2013).
Quality of life (QoL) is a further theoretical and clinical issue
relevant in ALS that could reasonably be directly associated with
physical decline. Several studies suggest, conversely, that ALS
patients’ QoL is independent of physical impairment (Simmons
et al., 2000; Palmieri et al., 2010b; Pagnini, 2013), a phenomenon
known as “disability paradox” (Carr and Higginson, 2001),
although this relationship is still unclear and motor disability
or ALS physical consequences are likely to play a crucial role
in determining QoL (Ganzini et al., 1999; Lo Coco et al., 2005).
QoL has also been negatively associated to psychological variables
such as suffering, sense of burden and hopelessness and positively
related mainly to spirituality (McLeod and Clarke, 2007; Pagnini
et al., 2011), caregiver relations (Chiò et al., 2004), and mindful
attitude (i.e., not evaluating a situation or a context only through
previous categorizations, but actively making new distinctions by
assuming multiple viewpoints and perspectives; Pagnini et al.,
2014a). Fegg et al. (2005) and Roach et al. (2009), highlight
a usually undervalued viewpoint, i.e., personality and personal
attitudes strongly modulate and shape in a unique manner the
possible reactions to ALS.
It is extremely complex to disentangle the specific role
of psychological variables, including anxiety, depression,
and subjectively perceived QoL from peculiar individual
characteristics and physical impairment. It is common clinical
experience that these dimensions, in ALS, are very tightly
interconnected in a dynamic and reciprocally causative way,
forming a circular system not yet thoroughly studied.
Indeed, the great physical burden induced by ALS easily
implies negative psychological reactions according to individual
traits and attitudes, which, in turn, could weigh on the physical
level. This latter aspect has an enormous importance in a disease
that substantially lacks medical treatment (Beghi et al., 2011) and
reliable physical prognostic factors (Creemers et al., 2014).
The evidence for the strong relation between psychological
status and physical outcome in ALS was first provided by a
seminal, cross-sectional longitudinal study by McDonald et al.
(1994), who found that patients with psychological distress
showed a significantly greater risk of mortality than those with
higher psychological well-being. Similarly, Johnston et al. (1999)
and Krampe et al. (2008) found that mood and personality
traits can strongly influence the survival rate of ALS patients.
Recently, Pagnini et al. (2014a) showed on a large sample of
people with ALS that a mindful attitude attenuates the ALS
progression.
It is easy to imagine how being affected by ALS can have
devastating psychological impact not only on patients but also
on their families, and mostly on their primary caregivers, which
are as well at risk of developing depressive and anxiety reactions
(Pagnini et al., 2010, 2011; Cipolletta and Amicucci, 2014). It
was first reported, in the seminal results by Chiò and his team
(Gauthier et al., 2007; Vignola et al., 2008), that whilst in patients
depression, anxiety and QoL remained substantially steady, in
caregivers there was a significant decrease of Qol and an increase
of anxiety and depression along disease progression.
However, notwithstanding the potentially great relevance of
the topic, scientific literature quite completely neglected research
on the efficacy of psychological interventions. Pagnini et al.
(2012c) recently called the scientific community via ALS leading
journal to fill this void, highlighting the importance of developing
“best practices” for the improvement of QoL and the reduction of
psychological distress in ALS patients.
As a first response to this call, Palmieri et al. (2013) published a
pilot study on psychodynamic-oriented psychological treatment
on ALS, showing the efficacy of a hypnosis intervention
together with a self-hypnosis training protocol. The efficacy
was proved by measuring pre-post levels of anxiety, depression,
QoL, and perceived changes of the aforementioned secondary
physical symptoms. Improvements in caregivers’ anxiety and
depression, probably as a consequence of patients’ psychological
and perceived physical symptomatology improvement, were
also observed. In a further, recent study by Averill et al.
(2013), a structural emotional disclosure intervention was
proposed to patients with ALS. Authors found their treatment
to improve psychological well-being, but argued that their kind
of intervention may only be helpful for ALS patients who were
unable to express emotions or who had ambivalent attitude about
expressing emotion to others. Díaz et al. (2014) demonstrated
the benefit, in terms of both anxiety and depression levels, of
an integrated intervention based on counseling and cognitive
behavioral therapy.
Similarly, Pagnini and colleagues are collecting data from
a randomized controlled trial to evaluate the effects of an
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ALS-specific meditation training (Pagnini et al., 2014b) on
well-being of people with ALS and their caregivers.
Thus, the few and recent research efforts on psychological
intervention on ALS displayed very encouraging results,
nonetheless they are deeply different in terms of adopted
psychological approach, methodology employed and measures
used to evaluate the change. Moreover, peculiar individual
characteristics that may mediate the change have never been
specifically assessed, and no long-term disease progression
implications have been studied, so far, in correspondence to
specific psychological treatment.
Our aim is to extend our previous (Palmieri et al.,
2013) hypnosis-based intervention to a broader ALS group,
investigating the longitudinal, long-term effects of intervention
on patients and their caregivers, and taking into account the
impact on disease progression as well as the influence of
individual aspects.
In the direction of this latter goal, we privileged a
psychodynamic approach to highlight personality features that
could mediate the adaptation to the disease, specifically by
focusing on defense mechanisms, which offer an interesting
insight into the ego’s psychological functioning.
In synthesis, we studied the long-term effects of a brief
psychodynamic hypnosis-based intervention on patients with
ALS, mainly in terms of their psychopathological and physical
symptoms as well as its resonance on caregivers. As a first
hypothesis, in line with previous data (Palmieri et al., 2013),
we expected positive changes on patients’ anxiety, depression,
and QoL and that these changes, as measured after the
psychodynamic hypnosis-based intervention, would keep stable
after 3 and 6 months. Secondly, on the basis of previous
results linking psychological well-being and disease progression
(McDonald et al., 1994; Johnston et al., 1999; Krampe et al.,
2008; Pagnini et al., 2014a), we investigated the possibility of a
positive physical effect on disease progression in the treatment
group in comparison to the control group. Thirdly, we further
hypothesized that these effects of the treatment on patients would
also have, as well, an indirect beneficial impact on caregivers’
anxiety and depression levels.
Finally, we hypothesized that intrapsychic dynamic factors,
such as defense mechanisms, could also represent a starting point
in order to take into account both the strictly nomothetic and
the idiographic perspectives as complementary (Salvatore and
Valsiner, 2010) since the uniqueness of psychological phenomena
requires characterizing the dynamics of the individual cases while
striving for generalization.
Methods
Participants
Fifteen consecutive volunteering patients with ALS—as members
of the treatment group—their respective primary caregivers, and
15 patients with ALS—as control subjects—were recruited via
the Motor Neuron Disease Center of the University of Padova
Hospital. In synthesis, a total of 45 individuals participated in
the study. Participants were informed about the study’s purpose
and methods and signed informed consent to the study protocol,
which was approved by the Ethical Committee of the University
of Padova, and carried out in accordance with the principles of
the Helsinki Declaration as revised in 1983.
The patients in the treatment group were 7 males and 8
females, with ages ranging from 43 to 73 years (M = 55.3,
SD = 8.72); the mean time since diagnosis ranged between 2
and 37 months (M = 14.79; SD = 11.05); 11 patients had limbic
onset, while 4 had bulbar onset; 4 patients were treated with low
dosage antidepressant, 1 patient with anxiolytic, and 11 patients
were treated with Rilutek. One of the patients died 6 months after
the recruitment, thus only available data was analyzed for this
patient. Their caregivers were 12 spouses (5 males, 7 females) and
3 daughters.
The patients in the control group were selected among the
availableMotor NeuronDisease Centre’s longitudinal dataset and
were matched for functional disability (ALS-FRS-r; Cedarbaum
et al., 1999), age, gender, onset site, time from onset, absence of
any cognitive impairment, and were not receiving psychological
assistance during the observational time range.
Inclusion criteria for all patients were to have sporadic ALS
fulfilling the revised El Escorial criteria for clinically probable
or definite ALS (Brooks et al., 2000). Exclusion criteria for
patients were the presence of significant neuropsychological
dysfunctions or alterations if compared to normative data, while
for both patients and caregivers, the presence of concomitant
psychiatric or neurological illness, and current use of high-dose
psychoactivemedications would lead to exclusion. No participant
was excluded by these means.
Measures
To assess defense mechanism profile, and thus infer
developmental levels in a psychodynamic perspective, we
used the Defense Style Questionnaire (DSQ; Bond et al., 1983).
The DSQ is a widely used self-report measure of empirically
derived groupings of defense mechanism ranked on an adaptive
hierarchy. The questionnaire consists of 40 items on a nine point
Likert scale, ranging from “Completely Agree” to “Completely
Disagree.” Four defensive styles labeled maladaptive, image-
distorting, self-sacrifice, and adaptive are evaluated. Authors of
the Italian validation of the questionnaire (San Martini et al.,
2004) suggested mostly using the maladaptive subscale since it
has the most items and shows higher reliability.
Trance depth and hypnotizability were assessed through
the Hypnoidal State Score (HSS) of the Phenomenology of
Consciousness Inventory (PCI; Pekala and Levine, 1982; Pekala,
1991). The PCI is a 53-item self-report inventory that maps
12 major and 14minor dimensions of subjective experience. In
addition to quantifying the experience of being hypnotized, this
measure describes various aspects of subjective experience, such
as imagery, affects, internal dialog, and alterations in awareness,
which were used to tailor subsequent hypnotic interventions
according to the patients’ features.
The Hospital Anxiety and Depression Scale (HADS; Zigmond
and Snaith, 1983) is a broadly used and reliable (Bjelland et al.,
2002) self-report measure for caseness and symptom severity of
anxiety disorders and depression. It consists of two subscales of
7 items each ranging from 0 to 3: HADS-A, assessing anxiety
Frontiers in Psychology | www.frontiersin.org 3 June 2015 | Volume 6 | Article 822
Kleinbub et al. Hypnosis treatment in ALS
and HADS-D for depressive symptoms. Among the wide range
of generic depression scales employed in ALS context, the
HADS items content seem to be less prone to be distorted
by ALS’ somatic impairments compared to other common
depression measures (Pagnini et al., 2014c). Furthermore, a
motor neuron disease’s specific version of the HADS has
been developed and quantitatively confirmed using Rasch
analysis in a study by Gibbons et al. (2011), providing revised
scoring and cut-offs that were used for patients in the present
study.
The Amyotrophic Lateral Sclerosis Specific Quality of Life—
revised (ALSSQOL-r; Felgoise et al., 2009; Pagnini and Simmons,
2010), was used to assess different dimensions of health-related
QoL. The ALSSQOL-r is a 46 item disease-specific questionnaire
using a 0–10 point Likert scale, with 0 being the least desirable
situation, and 10 being the most desirable. It consists of six
subscales: Negative Emotion, Interaction with People and the
Environment, Intimacy, Religiosity, Physical Symptoms, and
Bulbar Function; a Total score, including all the items can be
computed and was used in analyses. The ALSSQOL-r was chosen
since it provides insights into psychological aspects, spirituality
and social issues associated with the disease (Simmons et al.,
2006).
Functional impairment owing to ALS was evaluated using the
ALS-Functional Rating Scale Revised (ALS-FRS-R; Cedarbaum
et al., 1999), which represents the gold standard for neurological
evaluation of physical decline imposed by the disease. It consists
of 12 items with scores ranging from 0 to 4, with a maximum
achievable score of 48 (0 = total disability, 48 = normal)
that measures bulbar, upper-extremity, lower-extremity, and
respiratory functions.
Procedure and Intervention
Patients underwent complete neurological examination and
exhaustive neurocognitive assessment on the same day, about 2
weeks before the psychological treatment, respectively performed
by a trained expert neurologist and neuropsychologist with long-
term experience with ALS. These evaluations were performed as
part of the standardized diagnostic routine at the Motor Neuron
Disease Center.
A few days after examination, fully eligible patients of
the treatment group underwent a clinical interview performed
by a psychotherapist experienced in ALS. This interview was
aimed to assess patients’ defensive styles (through the DSQ
questionnaire) and personality characteristics, crucial in shaping
the psychological intervention planning. In this context, patients
were encouraged to share possible doubts or curiosity about
theoretical premises and expected outcomes, in order to fully
inform them about the study and to build clinical alliance. An
analogous clinical interview was performed by psychotherapists
with caregivers.
The intervention protocol consisted of 4 weekly domiciliary
sessions of hypnosis treatment. Each session was conducted by
a trained operator in Ericksonian hypnosis accompanied by a
further psychologist who administered all the questionnaires
and did not remain in the same room during treatment. Each
hypnotic session consisted of three phases: the first one was
a standardized hypnotic induction based on well-established
ideodynamic techniques (Bernheim, 1880) and focused onmind-
body relaxation, lasting about 20min. The second, core phase,
lasting from 30 to 45min, consisted in the administration of
therapeutic metaphors, guided visual imagery, and direct and
indirect suggestions individually tailored on the basis of the needs
of each patient. The conclusive phase of each session consisted
of anchoring suggestions aimed to teach self-hypnosis, followed
by a slow, guided return to a completely awake state of full
consciousness, lasting about 10min.
While the individual suggestions and metaphors were
specifically chosen on a per-patient basis, according to their
evolving clinical condition, personality and history, the four
sessions were based on fixed themes, common to every patient.
In the first session, labeled “safe place,” the suggestions and
imagery were oriented to a safe and quiet place where the
patient could allow his own body and mind to rest and recover
in deep relaxation. In the second session, labeled “awareness,”
the suggestions were focused on developing awareness of
individual thoughts, emotions and soothing body’s perceptions
like the breathing rate. In the third session, labeled “life chain,”
the suggestions were directed to the change of time focus,
and to images of the patients’ own familial generations. The
fourth and final session, labeled “perceptive,” was focused on
various imagined perceptions associated to positive emotions and
metaphors. After each hypnosis session, perceived trance depth
was assessed through the PCI.
The first phase standardized induction, common to all
sessions and for all patients, was recorded on an audio compact
disk and was left for each patient to listen to in order to
enhance self-hypnosis. Patients were encouraged to practice self-
hypnosis at least once every day. The whole procedure, including
self-hypnosis training, was partially inspired by the protocol
by Jensen et al. (2009), Jensen (2011) successfully applied on
patients affected by multiple sclerosis in terms of increased
well-being.
In synthesis, before the first session and in each follow-
up, depression, anxiety levels (by means of HADS) and quality
of life (by means of ALSSQOL-r) were assessed. HADS was
administered also to caregivers on these occasions. DSQ was
assessed only at the preliminary psychological interview, while
PCI was administered after each hypnotic session, as it is a
specific evaluation of the hypnotic experience.
Information about the presence of the most common ALS
secondary symptoms, i.e., pain, sleep disorders, emotional
lability, and fasciculations, was verbally collected by the
psychologist at the beginning and at the end of treatment.
From an experimental design perspective, outcome variables
were anxiety, depression (both for the patients being treated
and their caregivers), QoL, and functional disability. These
were measured before the intervention (T0), after the last
domiciliary session (T1) and on two follow-ups after three
(T2), and six (T3) months from the treatment. Since physical
functioning alterations, as assessed by ALSFR-r are not
appreciable after just 1 month, measurements were collected
only at T0, T2, and T3 for both treatment and control patient
groups.
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Statistical Analysis
Bayesian mixed-models methods were chosen because they offer
distinct advantages over classic NHST approaches, such as amore
straightforward interpretation of the results (Dienes, 2011), a
better handling of outliers and multiple comparisons (Gelman
et al., 2012; Aguinis et al., 2013). Furthermore, relevantly to
our design, this approach is more robust with small samples
and relies on fewer and less strict assumptions on the data
(Hoijtink et al., 2008). For a thorough review of the advantages of
Bayesian inference in psychological research, see Wagenmakers
et al. (2008).
All the analyses were performed with R statistical software,
version 3.1.1 (R Core Team, 2014) through the “BayesFactor”
package v.0.9.8 (Morey et al., 2014), using non-informative
priors. All the Markov Chain Monte Carlo simulations were run
with 100,000 iterations.
Regression Analyses
For each of our dependent variables, i.e., HADS-A and HADS-D,
ALSFR-r andALSSQOL-r we performed a Bayesian linearmixed-
model regression analysis, considering subjects as a random
factor (Id) and observation time-points (labeled “Time”), months
since diagnosis, HSS score, DSQ scores, psychopharmacological
drugs usage, self-hypnosis practice, and their interactions as fixed
factors.We computed a Bayes Factor (BF) of every possiblemodel
from our factors, against the simplest model with only the Id
random factor. We then chose the most parsimonious model that
was not less supported by data than 3 times the one with the
highest overall evidence. This cut-off was chosen since smaller
BF are described in literature (Jeffreys, 1961) as indicating a
“barely worth mentioning,” and not “substantial” evidence for
the model. The models selected through this statistical approach
were also valued in the light of their theoretical soundness against
similarly evident models. These two criteria always converged
in the choosing of the best models. Finally, we computed the
posterior distributions, quantifying uncertainty, for each of the
parameters of the chosen models.
Groups Comparison
The comparison between the treatment and control groups were
performed through Bayesian hypothesis testing (Rouder et al.,
2009; Kruschke andMeredith, 2014).We estimated the difference
in means between the two groups ALSFRS-r decline (T3minus
T0 scores) and computed its posterior probability distribution
to assess uncertainty. From this distribution, the mean credible
value was taken as the best guess of the actual difference and the
95%Highest Density Interval (HDI) as the range where the actual
difference is with 95% credibility.
Results
Patients and Caregiver Psychological
Measurement
Before treatment (T0), patients had a mean HADS-A score
of 7.60 (SD = 3.94), 3 patients’ score was in the range
for “borderline” cases of anxiety, and 6 patients’ score was
higher than the “case level” cut-off. After the 6 months follow-
up (T3), the mean score was 4.50 (SD = 2.62) and only
1 patient’s score was in the range for “borderline” cases of
anxiety, and 1 patient’s score was higher than the “case level”
cut-off.
Before treatment (T0), patients had a mean HADS-D score
of 3.27 (SD = 1.98), 5 patients’ score was in the range for
“borderline” cases for depression, while no patients’ score was
higher than the “case level” cut-off. After the 6 months follow-
up (T3), the mean score was 2.64 (SD = 1.91) and 3 patient’s
score was in the range for “borderline” cases for depression,
and none of the patient’s score was higher than the “case level”
cut-off.
HADS scores for the treatment group are presented in
Figure 1. The deceased patient did not have an anxiety or
depression score over the cut-offs at any measured time.
ALSSQOL-r scores (Figure 2) were in line with the normative
data for ALS patients (Felgoise et al., 2009; Pagnini and Simmons,
FIGURE 1 | Patients’ HADS anxiety and depression scores boxplots at
all time points. Scoring and cut-offs are based on the revised version for
MND patients.
FIGURE 2 | Patients’ ALSSQOL-r total scores for all time points are
reported in the boxplots, the lines represents the individual subscales.
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2010) with amean total score of 6.83 (SD= 1.10) at T0 and of 7.07
(SD= 1.14) at T3.
Mean ALSFRS-r score at T0 was 33.13 (SD = 9.88) for the
treatment group and 31.27 (SD = 3.90) for the control group;
at T3 these mean scores declined to 31.00 (SD = 8.13) for
the treatment group and to 23.00 (SD = 7.25) for the control
group.
The DSQ scores, measured at baseline, showed a very high
defensive behavior in treatment group’s patients. Specifically the
maladaptive (M = 6.90, SD = 1.04) and image-distorting (M =
6.73, SD= 0.74) subscales scores, assessing the use of less mature
defense mechanisms, were found to be more than the double of
the normative data scores for the Italian population (San Martini
et al., 2004). Adaptive subscale scores (M = 3.84, SD = 1.36),
in contrast, were comparable to the normative data. The mean
scores for patients’ and caregivers’ individual defense mechanism
are reported in Table 1.
For each patient, the average HSS score of the four hypnotic
sessions was calculated. All the patients were able to successfully
achieve an adequate trance depth: 5 out of 15 patients were able
to enter a mild hypnoidal state (HSS between 3 and 5), and
the remaining 10 patients a moderately hypnoidal state (HSS
between 5 and 7).
Before treatment (T0), caregivers had a mean HADS-A score
of 9.13 (SD = 3.72), 3 caregivers’ score was in the range for
TABLE 1 | Individual defense mechanisms’ mean scores of patients and
caregivers as assessed by Defense Style Questionnaire at baseline.
Defense style Defense mechanisms Patients Caregivers
M SD M SD
Maladaptive Acting out 6.80 1.70 6.19 1.60
Undoing 6.40 1.84 6.69 1.91
Passive aggressive 6.69 1.42 6.53 1.35
Consumption 7.45 2.02 7.24 1.57
Fantasy 7.29 2.46 4.50 2.69
Projective identification 8.00 1.81 8.21 2.01
Help-rejection 6.04 1.94 5.83 1.98
Projection 7.56 0.91 7.00 1.09
Regression 7.04 1.75 6.39 2.29
Withdrawal 5.07 2.85 4.05 2.25
Somatization 7.71 2.31 7.14 2.33
Image-distorting Denial 6.17 1.70 6.05 1.29
Isolation 5.88 1.36 4.66 1.73
Omnipotence 7.62 1.04 7.23 1.22
Splitting 7.24 1.52 5.86 1.87
Adaptive Affiliation 6.40 1.39 5.11 2.56
Anticipation 3.10 1.84 4.04 2.29
Primitive idealization 5.32 3.12 5.14 2.70
Task orientation 3.33 2.78 2.32 1.38
Pseudo altruism 2.20 1.90 2.50 2.20
Suppression 3.90 2.23 3.79 1.87
Sublimation 5.47 3.38 4.14 3.11
“borderline” cases of anxiety, and 7 caregivers’ score was higher
than the “case level” cut-off. After the 6 months follow-up (T3),
the mean score was 5.07 (SD= 3.67) and only 1 caregivers’ score
was in the range for “borderline” cases of anxiety, and 2 caregivers
score was higher than the “case level” cut-off.
Before treatment (T0), caregivers had a mean HADS-D score
of 4.60 (SD = 3.87), 1 caregiver’s score was in the range for
“borderline” cases for depression, while another 1 caregiver’s
score was higher than the “case level” cut-off. After the 6 months
follow-up (T3), the mean score was 2.50 (SD = 3.03) and 2
caregivers’ score was in the range for “borderline” cases for
depression, and none of the caregivers score was higher than the
“case level” cut-off. HADS scores for the caregivers group are
presented in Figure 3.
Psychological Wellbeing of ALS Patients:
Longitudinal Results
Anxiety
The best model selected through the Bayesian linear regression
showed a strong effect of the treatment (Time factor) and of
the DSQ maladaptive style score but no interaction factors.
None of the other considered moderators were present in
the most plausible models. Figure 4, representing the posterior
distributions of HADS-A means at the different time points for
the selected model, shows that the reduction in anxiety scores
after the treatment kept stable at T2 and T3.
The model showed an overall good fit [BF against “Id only”
model = 874, R2 = 0.79, Residual Standard Error (RSE) =
1.92, model parameters are reported in Table 2]; additional Bayes
Factors are reported in Figure 5.
Depression
While the data actually showed a possible reduction in depression
after the treatment, patients’ depression scores at T2 increased
again at pre-treatment levels (Figure 1). None of the considered
factors in regression analysis showed a relevant linear effect on
depression.
FIGURE 3 | Caregivers’ HADS anxiety and depression scores boxplots
at all time points. Scoring and cut-offs are based on the original scale.
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FIGURE 4 | Posterior distributions of anxiety means at the different
time points. The 95% HDI represents the area with the most credibility for the
exact value. Graphical inspection clearly evidence the decrease in the HADS
anxiety score after the treatment, and that this improvement was maintained in
the further follow-ups.
TABLE 2 | Posterior parameters for HADS-Anxiety best regression model
in patients.
Parameter Mean SD SE
Intercept 5.404 0.717 0.002
T0 1.902 0.450 0.002
T1 −0.460 0.401 0.001
T2 −0.638 0.404 0.001
T3 −0.804 0.418 0.001
DSQ–maladaptive −1.066 0.686 0.003
Sigma2 3.665 0.846 0.005
Quality of Life
The best model for the ALSSQOL-R QoL total score showed a
relevant, although small, effect of treatment. The score improved
at T1 and T2, while at T3 decreased again toward the pre-
treatment score. This trend of the Total score was similarly found
in most subscales, with the exception of the “bulbar” subscale
score, which showed a constant decline, and the “intimacy”
subscale score which showed an amelioration only at T2 and kept
stable at T3 (Figure 2).
The selected model, with QOL predicted by Time
and Id, showed an overall good fit (BF against “Id
only” model = 8.86, R2 = 0.82, RSE = 0.45, model
parameters are reported in Table 3). None of the other
considered moderators were present in the most plausible
models.
Decline of Physical Functions
For both the patients’ groups we computed ALSFRS-r difference
scores between pre-treatment and the 6 month’s follow up
(Figure 6). Treatment (M = −3.98, SD = 3.49) and control
group’s (M = −8.64, SD = 4.80) scores were compared through
Bayesian estimation. The computed posterior for the difference
in groups’ means showed a credible average difference of −4.63
FIGURE 5 | Bayes Factors of the chosen model for anxiety in patients
and its simpler nested models against the null model. The bars, on
logarithmic scale, represents the ratio of evidence between the different
models. Thus, by visual comparison, the weight of each single factor can be
inferred.
TABLE 3 | Posterior parameters for ALS Specific Quality of Life-revised
questionnaire best regression model for patients.
Parameter Mean SD SE
Intercept 6.579 0.269 0.001
T0 −0.232 0.097 <0.001
T1 0.162 0.093 <0.001
T2 0.167 0.093 <0.001
T3 −0.097 0.093 <0.001
Sigma2 0.202 0.047 <0.001
with 95%HDI (−8.213,−1.02), whichmeans a 99.3% probability
of the real difference value to be smaller than zero (Figure 7). The
computed Bayes Factor against the “no difference” null model
was 6.70, which indicates a substantial evidence in favor of the
“difference” model.
Furthermore, we run Bayesian linear mixed-models
regression analysis on the treatment group to assess if the
decline of the ALSFRS-r score could be predicted by our
psychological measures or other factors. The best fitting model,
though, showed no effect aside the decline in time (BF against “Id
only” model = 7036, R2 = 0.95, RSE = 2.01, model parameters
are reported in Table 4).
Perceived severity of secondary symptoms, as qualitatively
collected in clinical interviews, were compared between pre
and post treatment levels: sleep disorders improved in 4 out
of 5 patients, pain and cramps improved in 11 out of 14
patients, fasciculations improved in 8 out of 12 patients and
emotional lability improved in all of the 7 patients presenting
such symptom.
Psychological Wellbeing of Caregivers
Anxiety
The best model selected through the Bayesian linear regression
showed an effect of the treatment (Time factor) and the DSQ
maladaptive score on caregivers’ anxiety, but no interaction
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FIGURE 6 | ALSFRS-r 6 months difference scores boxplots in control
and treatment groups.
FIGURE 7 | The computed posterior distribution of the true difference
in means between experimental and control group decline at 6
months. Since zero lies outside the 95% HDI (the interval that contains the
exact value with the most credibility), it can be inferred that the two groups’
decline at 6 months is credibly different.
factors. The model shows an overall good fit (BF against
“Id only” model > 1000, R2 = 0.79, RSE = 1.90, model
parameters are reported inTable 5), additional BF are reported in
Figure 8.
Depression
The best model selected through the Bayesian linear regression
showed an effect of the DSQ maladaptive score and of the
treatment (Time factor) on caregivers’ depression, but no
interaction factors. The model shows an overall good fit (BF
against “Id only” model > 1000, R2 = 0.79, RSE = 1.90, model
parameters are reported in Table 6), additional BF are reported
in Figure 9.
TABLE 4 | Posterior parameters for ALS Functional Rating Scale-revised
best model.
Parameter Mean SD SE
Intercept 31.642 2.697 0.008
T0 1.358 0.441 0.002
T1 1.362 0.441 0.002
T2 −0.481 0.429 0.001
T3 −2.239 0.476 0.002
Sigma2 4.025 0.956 0.005
TABLE 5 | Posterior parameters for HADS-Anxiety best model in
caregivers.
Parameter Mean SD SE
Intercept 6.711 0.831 0.003
T0 2.106 0.449 0.002
T1 0.928 0.428 0.001
T2 −1.381 0.447 0.002
T3 −1.653 0.451 0.002
DSQ–maladaptive −1.406 0.792 0.004
Sigma2 3.606 0.902 0.005
FIGURE 8 | Bayes Factors of the chosen model for anxiety in
caregivers and its simpler nested models against the null model. The
bars, on logarithmic scale, represents the ratio of evidence between the
different models. Thus, by visual comparison, the weight of each single factor
can be inferred.
Discussion
The primary goal of the present study was to provide evidence
on the efficacy of a hypnosis-based intervention on patients with
ALS. Confirming our hypotheses, the results of this longitudinal
investigation showed an improvement in wellbeing of patients
with ALS, essentially in line with preliminary data observed
in our pilot study (Palmieri et al., 2013). Namely, after our
hypnotic treatment and autohypnosis training, we observed an
improvement in anxiety and depression scores, as measured by
HADS (Zigmond and Snaith, 1983). Regression analysis clearly
described the improvement in anxiety score, persisting also after
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TABLE 6 | Posterior parameters for HADS-Depression best model in
caregivers.
Parameter Mean SD SE
Intercept 3.619 0.711 0.002
T0 0.787 0.362 0.001
T1 0.246 0.330 0.001
T2 −0.411 0.345 0.001
T3 −0.622 0.357 0.001
DSQ–maladaptive −2.065 0.748 0.004
Sigma2 2.623 0.639 0.004
FIGURE 9 | Bayes Factors of the chosen model for depression in
caregivers and its simpler nested models against the null model. The
bars, on logarithmic scale, represents the ratio of evidence between the
different models. Thus, by visual comparison, the weight of each single factor
can be inferred.
3 and 6 months, while depression score returned to the pre-
treatment level at 3months not allowing for any of the considered
factors to describe satisfyingly its longitudinal trend.
With regard to QoL, as measured by ALSSQOL-r (Felgoise
et al., 2009) total score, our best possible regression model
described an evident effect of intervention, although of only
moderate extent. Specifically we observed an improvement at the
end of the treatment and after 3 months, while at the 6-months
follow-up the scores turned slightly back toward baseline levels.
ALSSQOL-r’s individual subscales showed the same trend, except
for the “intimacy” subscale, which improved only at 3 months
and did not regress at the last follow-up; the “bulbar” subscale,
which showed a constant decline; and the “interaction” subscale,
which already returned to baseline levels after 3 months.
Bayesian mixed-models regression analysis described no
relevant effects of the mild psychopharmacological treatment
assumed by five of our patients, nor of their different
hypnotizability levels, as assessed by PCI (Pekala, 1991).
Analogously, the constancy in the practicing of self-hypnosis
after the treatment did not revealed any effect in the study
outcomes.
Furthermore, our hypotheses of a link between psychological
intervention and physical decline, based on previous studies
on ALS describing the psychological status as a moderator for
disease progression/survival rate, were confirmed. Specifically
we observed an improvement in perceived secondary physical
symptomatology immediately after the treatment and, notably,
a slower functionality loss, comparing our treated group to a
ALS control group, one-by-one matched in terms of age, gender,
onset site, time from onset, ALSFRS-r (Cedarbaum et al., 1999)
score at baseline and absence of any cognitive impairment. DSQ
(Bond et al., 1983) questionnaire was used to assess defense
mechanisms profile to individuate the role of intrapsychic factor
on psychological status; the DSQ consists of three subscales
corresponding to three major defense styles: image distorting,
maladaptive, and adaptive, sorted by increasing adaptivity. The
scores observed in our patients suggest they strongly rely on the
most primitive spectrum of the defense styles. We found some
peculiar defense mechanism to be much more represented than
others, and overall, patients’ scores in maladaptive and image
distorting subscale were about the double than those reported in
the normative data, while the scores for the adaptive style were
comparable to those of the normal population. The treatment
had a positive effect on caregivers’ anxiety and depression scores
as well. This effect was found to persist after 3 and 6 months
from the intervention. The DSQ scores regarding the caregivers
group substantially mirrored those found for patients with the
exception of the “fantasy” defense mechanism, which had a
very high score in the patients’ group only. Additionally, the
maladaptive style score was found to have an effect, constant in
time, on anxiety level in patients and on anxiety and depression
levels in caregivers. Notably we found no interaction effect
between the improvement in time and the DSQ scores either
in patients or in caregivers, meaning that the efficacy of the
treatment was independent from the amount and type of defenses
used.
Each of these aforementioned results, in the context of our
main hypotheses, could open a very wide area of discussion,
with in-depth theoretical analysis and consequent clinical
applications. Among the most relevant results, the firsts that
may deserve such a detailed focus are the positive effects of the
treatment. Before the intervention, anxiety appeared to be the
greater psychological source of suffering in the treatment group’s
patients, especially in comparison to depression. Specifically,
the clear reduction of anxiety scores, immediately after the
1-month hypnotic treatment, was observed to persist during
all our data collection period. Consistently with these results,
several evidences converge in suggesting that hypnotic state and
hypnotizability could be strongly moderated by oxytocin (Bryant
et al., 2012; Bryant and Hung, 2013), a hormone implicated,
indeed, in social bonding and in the reduction of social anxiety
(Radke et al., 2013).
Before treatment, in contrast to anxiety, depression was found
at “borderline” levels at most.While the scores decreased after the
intervention, the observed depression level was probably too low,
at every time point, to appreciate a clearly evident final effect of
the treatment.
Although anxiety and depression are frequently described
as two strongly related dimensions in ALS literature (Vignola
et al., 2008; Atassi et al., 2011; Chen et al., 2015), their
different extent measured in our study, could be interpreted
in the light of the concerns raised by several authors about
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assessment methodologies, in particular for the evaluation of
depression levels (Wicks et al., 2007; Gibbons et al., 2011;
Gibbons and Young, 2012). Additionally, while undoubtedly
linked, anxiety and depression may reveal different complexities
regarding their clinical investigation and assessment, given
their peculiar nature and pathogenesis. From a psychodynamic
perspective, anxiety is typically experienced when a person feels
himself to be in impending danger, whether internal (as a
consequence of pulsional conflicts) or external (because of real
or presumed threats). It is a common clinical experience, other
than theoretical assumption, conversely, that depression is a
more sophisticate and rich phenomenon, which pervades many
life aspects. Furthermore, it is conceivable that the existential
despair caused by ALS together with the concomitant challenge
to live positively the remaining time, as described by many
patients, could generate conflicting feelings poorly represented
in the generic items of a standardized questionnaire. The
mourning process caused by the progressive and relentless
loss of patients’ physical functions generates overwhelming
experiences of demoralization, hopelessness, anger, and loss
of meaningfulness that should not be simply ascribed to
“depression” (Blackhall, 2012). Additionally, our current western
culture denies and censors the thought of death, even at an
institutional level, resulting for instance, in the lack of adequate
end-of-life policies, formalized procedures and professionals
training observed by Cipolletta and Oprandi (2014) in health
care organizations. Such a widespread cultural denial may have
relevant psychological consequences, such as the inability to
verbally express, or even consciously conceive, the dread caused
by the reality of their condition (Testoni et al., 2013). For all of
these reasons some aspects of depressive symptomatology may
have passed unnoticed.
QoL is as well one of the most important among the yet
achievable goals in the context of ALS psychological treatment.
In our results, we found that QoL, as a whole, showed a
clear immediate positive trend, slightly reverting 6 months
after treatment. When compared to the QoL questionnaire sub-
dimensions, the intimacy subscale revealed a clear amelioration
only 3 months after the treatment, and persisting for the whole
observation period. This delayed effect is probably associated
with the great improvement in anxiety and depression levels
observed in caregivers, which surprisingly kept stable at 6months
after patients’ treatment. Such a virtuous circle in which the better
psychological wellbeing of the patients positively influences
caregivers’ one and, vice versa, caregivers’ improvement shows a
positive impact on patients’ psychological status has already been
described in some published articles (Chiò et al., 2004, 2005; Lillo
et al., 2012; Pagnini et al., 2012b).
Overall, the burden experienced by the caregivers of patients
with ALS is often severe and they are at risk of developing
depressive and anxiety symptoms (Pagnini et al., 2010). In our
opinion, although representing a secondary outcome in our
experimental design, the results observed in regard to caregivers
may have great relevance also in terms of clinical practice.
As for the verbal content and the administration modality,
our hypnosis-based protocol based its theoretical premises on
well-established literature on hypnosis, already described as
effective in depressive symptomatology (Shih et al., 2009),
in anxiety (Saadat et al., 2006; Nash and Barnier, 2012), in
the improvement of QoL (Liossi and White, 2001) as well
in the treatment of many neurological diseases conditions
(Wahbeh et al., 2008). In particular, since suggestions are
the core mechanisms withstanding the hypnotic treatment,
it can be inferred that those specifically included in our
protocol could have promoted the psychological change in
patients.
Each of the four selected suggestions themes, while shaped
on patients’ individual features were conceived to have a role in
the conscious and unconscious dynamics, in order to promote
long-term benefit. For instance, thinking about the past and the
future has been described to lead to increased rumination and
well-being loss in ALS patients (Real et al., 2014). By means of
hypnosis it is possible to intervene in this painful process, leading
to a sense of hopelessness (Plahuta et al., 2002), through the
vivid recall of positive imagery of the past and the projection of
these symbolic representations into the future, a process which
allows to restructure the experience of the self in a coherent and
significant temporal dimension. This goal was pursued through
the “life-chain” suggestion, based on imageries of generations
of ancestors, which were represented behind each patient’s own
shoulders and the patients’ offspring and future generations in
front of them. These imageries, while evoking a feeling of hope,
triggers patients’ support functions, ideas of protection and help,
and therefore may reactivate secure attachment figures.
In this vain, many of our hypnotic inspirations included
in the suggestions also refer to the attachment theory, in
terms of relationships which provide secure-base and safe-haven
functions. Clear and stable decrement of patients’ anxiety levels,
which is one of the main outcome observed in our study, could
have partially been due to the symbolic representation of sources
of protection conceived in the attachment theory framework, as
suggested by Mikulincer et al. (2010).
Another relevant finding of our study is the attenuation of
the disease progression, after 6 months, in the treated patients
when compared to a well-matched ALS control group. As the
number of participants was relatively small, this potentially very
relevant finding should be considered cautiously, and requires
further investigations to be confirmed. However, this result
would be supported by those previous studies showing how a
poor psychological state is a significant predictor of subsequent
disability and can influence survival rate (McDonald et al., 1994;
Johnston et al., 1999; Krampe et al., 2008; Pagnini et al., 2014a).
This could be a broader mechanism, not only affecting the person
health-related choices, such as advance health care directive for
LTMV, as observed by Rabkin et al. (2006).
The association found between the attenuation in disease
progression and the concomitant psychological treatment can
have several interpretations. It is a fact that the central nervous
system changes during hypnosis have been documented by fMRI
and EEG studies, and there are many sites in the nervous system
in which the overall neural output to skeletal muscle can be
modified (Faymonville et al., 2006; Raz et al., 2006). Specifically,
hypnosis can have effects on physical parameters such as pain
threshold, inflammatory states (for an exhaustive review see
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Jensen et al., 2015), and, according to Rossi and colleagues, also
at a genomic level (Rossi, 2003).
Indeed, increasing evidence shows that psychophysiological
processes, as well as psychotherapy, have an impact on the brain
morpho-functional arrangement and genic expression (Benelli
et al., 2012; Morath et al., 2014).
However, many questions remain regarding the mechanism
that explain the effect of hypnosis in our study. Possibly,
the specific muscular relaxation suggestions included in our
protocol, could have played a role, independently from the
hypnotic phenomenon per se, in training patients not to overload,
and thus to partially preserve, the still innerved muscular
fibers.
While the hypnotic intervention proved efficacious in all
treated patients, we did not find any relevant effect of the PCI’s
HSS index, measuring the individual ability to reach a deeper
trance and strongly correlated to classic hypnosis measures,
such as the Harvard group scale of hypnotic susceptibility
(Pekala and Kumar, 1984, 1987; Forbes and Pekala, 1993),
not suitable in a clinical context. Although this result may
appear counter-intuitive, in the context of hypnotic research it
is not as surprising. The exact relationships between hypnosis
components (e.g., hypnotizability, suggestibility, dissociation,
relaxation, expectancy, compliance, etc.) are not yet well
understood, and high hypnotizability was not found to be
necessary, nor predictive for treatment efficacy in other hypnotic
intervention contexts as well (Carli et al., 2008).
Finally, particular attention has been devoted to individuate
the identification of the defense mechanisms employed by
patients, which inevitably modulate the ways the disease is faced,
and consequently the psychological reactions. Our data showed
an impressive strengthening of the primitive organizational
level of defense mechanisms, included in the “maladaptive” and
“image-distorting” styles; e.g., projection, regression, projective
identification, denial, omnipotence, etc.
A sort of “well-being paradox,” meaning that a person shows
an apparently good psychological health in the face of an
incurable disease, has been observed in terminal patients (Grehl
et al., 2011). This phenomenon could be explained by the massive
use of denial (i.e., a repudiation of a painfully shared reality and
the replacement of it with a more agreeable, individual, version),
classically described also in ALS patients (Brown and Mueller,
1970).
Weisman provides an interesting distinction between three
aspects of denial in terminal illness (Weisman, 1972). A “first
order” denial, in which patients deny the facts relative to his
illness; a second-order denial, which prevents the patients from
evaluating the extent and the implication of the disease; and
a third order denial directed to the image of death itself. In
this sense, denial mechanisms could be interpreted more in an
“adaptive,” rather than “primitive” perspective, in a context that
obliges patients to face their own mortality.
Preconceived notions regarding this frequently described
defense mechanism in ALS, such as “denial is good” or “denial
is bad” do not make sense in the clinical situation. Indeed,
denial could serve the patient well if it wards them off anxiety
or depression without interfering with treatment compliance or
the patient’s life goals (Straker, 1998). However, albeit denial
was intensively used, the most employed defense mechanism
observed in our sample was projection (i.e., attributing to others
tendencies originally located and identified within oneself, and
then condemned and disavowed), in particular in terms of
paranoid thinking. Items related to the idea of other people
posing a threat to the patients’ own physical and psychical life,
received extremely high scores (all patients scored 9 or 10, on a
10 points Likert scale), probably related to that painful feeling of
“punishment” wittily detected in clinical interviews with patients
by Oster and Pagnini (2012).
Lastly, we observed a strong reliance on the escapist “fantasy”
defense mechanism, already observed in patients with ALS by
Palmieri et al. (2010a) by means of projective measures. Results
of our regression analyses showed that the maladaptive style
score was the only factor, aside from treatment, that played
a significant role in moderating psychopathological symptoms.
Specifically acting as a buffer against the manifestation of
anxiety and depression, an effect that was constant in time
and active in both patients (although statistically sound only
for anxiety) and their caregivers, who showed a very similar
pattern of defense mechanisms. These data suggests that the
presence of projection and denial, as well as other archaic defense
mechanisms, could actually reveal an adaptive reaction to such
devastating conditions, and allow to better welcome further
treatment as opposed as to what usually happens in clinical
psychological practice with patients without physical diseases
(McWilliams, 2006).
Among the limitations of the study, the paucity of the
sample may restrict the generalizability of the study findings, yet
some characteristic of our protocol design represents innovative
strength points in respect to the small literature on ALS
psychological treatment. Firstly, the patients assessed in the
present study were screened for cognitive dysfunctions. This
is a relevant issue in the disease (Abrahams, 2013), which is
almost never considered in ALS psychological treatment, and
is an aspect that may potentially mask the severity and multi-
facetedness of psychopathology in these patients. Furthermore,
the chosen hypnotic treatment, together with self-hypnosis
training, allows for another important goal in the context of such
a pervasive disease as other psychological interventions, such
as cognitive therapy, require an interactive conversation, which
becomes eventually almost impossible as the disease progress
toward a locked-in state (Kurt et al., 2007). Self-hypnosis instead
is a skill that, once learned, can be reliably used without the
need of any muscular activity. In psychodynamic terms, entering
a state of self-hypnosis taught in a therapeutic context, allows
to reactivate an introjected representation of the therapist as
well, together with its associated supporting meanings of a safe
relationship.
In synthesis, we highlight the longitudinal, positive effects
of our brief psychodynamic treatment, both at psychological
level, and most strikingly, at physical level. Our data are similar,
for some aspects, to those recently described by Averill et al.
(2013); Díaz et al. (2014); Pagnini et al. (2014b), and their
teams for treatments, respectively based on expressive disclosure
approach, cognitive-behavioral therapy, and mindfulness
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meditation training. Still, to the best of our knowledge, this
is the first report of a positive long-term effect on disease’s
progression associated to a psychological intervention in these
patients.
On a theoretical level, we tried to approach the complexity of
the psychological dynamics in reaction to a devastating disease
such ALS, not by searching just for a common personality or
typical psychological patterns. We attempted instead to highlight
individual peculiarities and integrate them in every design step:
in the treatment, in data analysis, by controlling the subject
factor, and finally in the results interpretation, moving first
steps toward the goal of abductive reasoning (Salvatore and
Valsiner, 2010). The abductive generalization (Peirce, 1935),
that could represent the key to overcome the opposition
between nomothetic and idiographic perspectives, is not only
compatible, but arguably strictly interdependent with Bayesian
confirmation theory (Douven, 2011) on which the statistical
methods employed in our study are based, and we hope that these
dialog and perspective could represent the future directions in
this research field.
In the clinical practice perspective, patients and caregivers
should be aware that hypnotic interventions conjunctly to
training in self-hypnosis are relatively easy and inexpensive to
provide, and have a plethora of beneficial “side effects.” We hope
our findings could represents a helpful step in the construction
of “best clinical practice,” to better manage psychic and physical
plagues imposed by ALS disease to patients and their families.
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